Site Menu:
This is an archived Horseadvice.com Discussion. The parent article and menus are available on the navigation menu below: |
HorseAdvice.com » Diseases of Horses » Lameness » Diseases of the Lower Limb » Ringbone » |
Discussion on Arthramid | |
Author | Message |
Member: rosieint |
Posted on Saturday, Feb 4, 2017 - 7:47 pm: Hello,I would be grateful for your views on this new drug. Many thanks. Rosie |
Moderator: DrO |
Posted on Tuesday, Feb 7, 2017 - 8:14 am: Hello RosieP,This is a recent abstract that was not conducted by the company. The results were encouraging and it was helpful in cases of coffin joint OA. DrO Acta Vet Scand. 2015; 57(1): 20. Published online 2015 Apr 15. doi: 10.1186/s13028-015-0110-6 PMCID: PMC4403890 An international multi-centre prospective study on the efficacy of an intraarticular polyacrylamide hyDrOgel in horses with osteoarthritis: a 24 months follow-up Aziz Tnibar,corresponding author Hans Schougaard, Linus Camitz, Jonas Rasmussen, Marc Koene, Werner Jahn, and Bo Markussen Background Polyacrylamide hyDrOgel (PAAG) was evaluated recently to treat osteoarthritis (OA) in horses with highly encouraging results; however no long term field-study was done to explore its clinical efficacy and lasting effect. The objective of this study was to evaluate the efficacy of PAAG in improving clinical signs of OA in horses. We hypothesized that lameness grade would significantly improve and the effect would last at least 2 years in osteoarthritic joints treated with PAAG. Forty three horses older than 2 years with OA in only one joint based on clinical evaluation, intra-articular anaesthesia and imaging (radiography) were included in this study. Horses were injected with 2 ml of PAAG into the affected joint and were followed up at 1, 3, 6, 12 and 24 months. Efficacy of PAAG was evaluated by blinded clinical assessment of lameness. Adverse reactions to joint injection were assessed. Data relating to case details, type of activity, joint and limb involved, lameness duration, lameness grading, previous joint treatment, joint effusion grading, radiographic grading, and owner assessment were recorded. Factors associated with the outcome measure “lameness grading" were analyzed using generalized linear mixed model for logistic regression. Results At 1, 3, 6, 12 and 24 months follow-up, 59%, 69%, 79%, 81/% and 82.5% of horses were non-lame respectively. Reduction of joint effusion was observed over time. No side effect was observed in the treated joints. There was a significant decrease in lameness grade from baseline to 1, 3, 6, 12 and 24 months (P < 0.0001) and a significant positive association with joint effusion (P < 0.0001). Estimates for odds ratio (OR) showed that the effect of treatment increased over time (OR for lower lameness from month 1 to month 24 relative to baseline increased from 20 to 58). Conclusions PAAG significantly alleviated lameness and joint effusion in osteoarthritic joints. PAAG is a safe and lasting (at least 24 months) OA treatment in horses. PAAG is a promising new treatment for OA in horses. |